1. Israel Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd.

NRSNW
NeuroSense Therapeutics Ltd.US flagNASDAQ Capital Market
0.05
USD
- -
- -
1.23MMarket Cap
NeuroSense Therapeutics Ltd.
NRSNW
(NASDAQ Capital Market)

Recent

price

0.05

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.09
0.06
0.82
0.48
-0.11
0.11
-0.05
0.11
Book Value per Share
0.09
0.06
0.82
0.48
-0.11
0.11
-0.05
0.11
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-3
-4
-10
-10
-10
-11
-10
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
1
1
11
6
-1
2
-2
2
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
1
1
9
6
-2
3
-2
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-358.66
-83.62
-143.48
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
20
23
Market Capitalization
4
3
10

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
2
1
4
Cash, Cash Equivalents & STI
1
- -
3
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
4
2
Payables & Accruals
4
4
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
138.1%
-160.39%
Free Cash Flow
- -
104.15%
-24.26%
Net Income, GAAP
- -
41.77%
8.96%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
XOMA Corporation (XOMAO)
DNAPrint Genomics, Inc. (DNAG)
Atreca, Inc. (BCEL)
Fresh2 Group Limited (FRES)
Black Diamond Therapeutics, Inc. (BDTX)
LexaGene Holdings Inc. (0V43.L)
Business
NeuroSense Therapeutics Ltd. (NRSNW) is a clinical-stage biotechnology company focused on discovering and developing targeted therapeutics for neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease. The company offers PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib targeting microRNA dysregulation, iron accumulation and neuroinflammation in ALS and granted orphan drug designation by the FDA and EMA; CogniC, a combination drug addressing inflammation, oxidative stress and amyloid-β aggregation in Alzheimer's disease currently enrolling in a Phase 2 RoAD trial (NCT06185543); and StabiliC, a preclinical candidate for Parkinson's disease. NeuroSense Therapeutics operates primarily in the United States, Canada, Israel, Italy and internationally from its headquarters in Herzliya, Israel, where it was founded in 2017. Recent developments include entering a binding term sheet in December 2024 with a major global pharmaceutical partner for PrimeC development and commercialization in key markets with a definitive agreement anticipated in 2025; regaining Nasdaq stockholders' equity compliance in January 2025 following a $5 million private placement; reporting additional Phase 2b PARADIGM study data in February 2025 showing 40% slower functional decline and 74% improved survival in adherent patients; presenting biomarker data at the American Academy of Neurology in April 2025; scaling PrimeC manufacturing to commercial levels with a global CDMO in May 2025; completing a $500,000 private placement at a 40% market premium in September 2025; and preparing for a multinational Phase 3 ALS trial and new NOC/c submission to Health Canada in the second half of 2025.

Company News

Company News APIChatGPT

  • defenseworld.net

    NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December